Match tier
Confirmed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-10-04
H
Hanxin Lu
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Role not yet determined Is this you? Add your title
20 h-index
29 pubs
1,581 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Hanxin Lu's research focuses on the development and evaluation of novel therapeutic and preventive strategies, particularly in the areas of cardiovascular disease and immunology. Lu has investigated VXX-401, an investigational PCSK9 vaccine aimed at reducing low-density lipoprotein cholesterol (LDL-C) in non-human primates. Further research includes the preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide, another approach for managing cardiovascular risk factors.
Beyond cardiovascular health, Lu's work has also explored broader public health and disease mechanisms. This includes studies on the impact of social determinants, lifestyle, and environmental factors like air pollution on allergic diseases and their comorbidities, using multi-state analysis of prospective cohort data. Additionally, Lu has examined health information-seeking behaviors among specific demographic groups, such as Baby Boomers in Taiwan.
Lu's scholarship metrics indicate a significant body of work, with an h-index of 20, 29 total publications, and over 1,500 citations. Lu collaborates with other faculty members at the University of Central Arkansas, including Alexander Chen, Michael J. Rubach, and Mark E. McMurtrey, and leads a research group.
Metrics
- h-index: 20
- Publications: 29
- Citations: 1,581
Selected Publications
-
Impact of social determinants, lifestyle and air pollution on the allergic diseases and comorbidities: A multi-state analysis of a prospective cohort (2025)
-
Preventive Health Care Information Seeking Behaviors among Baby Boomers in Taiwan (2025)
-
Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide (2025)
-
A Study of Aesthetic Characteristics and Expressions of Photographic Art (2024)
-
VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys (2024)
-
VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE (2023)
-
Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge (2019)
-
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection (2019)
-
Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein (2019)
-
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge (2018)
-
A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age (2017)
-
Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults (2017)
-
Strategies for enhancing success in digital tablet use by older adults: A pilot study (2016)
-
Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice (2016)
-
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age (2015)
Collaboration Network
Top Collaborators
Gregory M. Glenn
Novavax (United States) (US)
11 shared publications
- A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
- Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats
- Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
- Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice
- A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age
Showing 5 of 11 shared publications
Gale Smith
Novavax (United States) (US)
11 shared publications
- A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
- Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats
- Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
- Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice
- Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
Showing 5 of 11 shared publications
David C. Flyer
Novavax (United States) (US)
7 shared publications
- A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
- Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats
- Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice
- An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization
- Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs
Showing 5 of 7 shared publications
Louis Fries
Novavax (United States) (US)
6 shared publications
- A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
- Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
- A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age
- Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
- An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization
Showing 5 of 6 shared publications
Eloi Kpamegan
Novavax (United States) (US)
6 shared publications
- A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
- Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
- Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice
- A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age
- Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
Showing 5 of 6 shared publications
John Brady
National Institutes of Health (US)
6 shared publications
- PCAF Interacts with Tax and Stimulates Tax Transactivation in a Histone Acetyltransferase-Independent Manner
- Tax Interacts with P-TEFb in a Novel Manner To Stimulate Human T-Lymphotropic Virus Type 1 Transcription
- Acetylation of Nucleosomal Histones by p300 Facilitates Transcription from Tax-Responsive Human T-Cell Leukemia Virus Type 1 Chromatin Template
- Tax Relieves Transcriptional Repression by Promoting Histone Deacetylase 1 Release from the Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat
- TFIID component TAF7 functionally interacts with both TFIIH and P-TEFb
Showing 5 of 6 shared publications
Somia P. Hickman
Novavax (United States) (US)
5 shared publications
- A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
- Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
- A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age
- Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
- Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs
Michael J. Massare
Novavax (United States) (US)
5 shared publications
- Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats
- Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice
- An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization
- Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein
- Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge
Pedro A. Piedra
Baylor College of Medicine (US)
5 shared publications
- A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
- Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
- A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age
- Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
- Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge
Mimi Guebre‐Xabier
Novavax (United States) (US)
4 shared publications
- Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection
- Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs
- Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge
- Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge
Bin Zhou
Novavax (United States) (US)
4 shared publications
- Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats
- Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
- Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice
- An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization
D. Nigel Thomas
Novavax (United States) (US)
4 shared publications
- A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
- Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
- A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age
- Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
R. Louis Schiltz
National Institutes of Health (US)
4 shared publications
- HDAC1 Acetylation Is Linked to Progressive Modulation of Steroid Receptor-Induced Gene Transcription
- PCAF Interacts with Tax and Stimulates Tax Transactivation in a Histone Acetyltransferase-Independent Manner
- Acetylation of Nucleosomal Histones by p300 Facilitates Transcription from Tax-Responsive Human T-Cell Leukemia Virus Type 1 Chromatin Template
- Tax Relieves Transcriptional Repression by Promoting Histone Deacetylase 1 Release from the Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat
Cynthia A. Pise-Masison
National Institutes of Health (US)
4 shared publications
- PCAF Interacts with Tax and Stimulates Tax Transactivation in a Histone Acetyltransferase-Independent Manner
- Acetylation of Nucleosomal Histones by p300 Facilitates Transcription from Tax-Responsive Human T-Cell Leukemia Virus Type 1 Chromatin Template
- Tax Relieves Transcriptional Repression by Promoting Histone Deacetylase 1 Release from the Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat
- Coactivator-Associated Arginine Methyltransferase 1 Enhances Transcriptional Activity ofthe Human T-Cell Lymphotropic Virus Type 1 Long Terminal Repeat through Direct Interactionwith Tax
Larry Ellingsworth
Novavax (United States) (US)
4 shared publications
- Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection
- Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge
- Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein
- Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge
Similar Researchers
Based on overlapping research topics
Esraa Shosha
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Metabolism and Genetic Disorders
Immune Response and Inflammation
Hannah Campbell
University of Central Arkansas
Cardiovascular Function and Risk Factors
Metabolism and Genetic Disorders
Immune Response and Inflammation
Jessica W. Barnes
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Public Health Research
Immune Response and Inflammation
Ting Liu
University of Arkansas at Fayetteville
Cardiovascular Function and Risk Factors
Metabolism and Genetic Disorders
Immune Response and Inflammation
Qingfang He
University of Arkansas at Little Rock
Cardiovascular Function and Risk Factors
Metabolism and Genetic Disorders
Public Health Research
Lucas R. Johnson
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Metabolism and Genetic Disorders
Immune Response and Inflammation